Time to establish a multicentre prospective study to resolve the question No longer is there argument that cervical screening can reduce deaths from cervical cancer. There is also agreement that the incidence of cervical intraepithelial neoplasia has risen appreciably in recent years' 2 and that without intervention deaths from cervical cancer in the 1990s will rise by 70% or more. The debate is now centring on what proportion of cases of cervical intraepithelial neoplasia will progress and over what period of time.
Introduction of the call and recall screening programme for cervical cancer in Britain in 1987 reflected a determined effort to detect the hidden pool of cervical intraepithelial neoplasia (and occult invasive carcinoma) but is beginning to highlight problems relating to the efficacy of cervical cytology and how to manage the woman with an abnormal smear result. Cervical cytology seems to be the only practical way of detecting cervical intraepithelial neoplasia, but even the best laboratories have admitted to a false negative rate of 10-15%-o and recent work suggests that this may be a gross underestimate. Giles et al screened women with both cytology and colposcopv and found that the prevalence of cervical intraepithelial neoplasia was 5% when detected by cytology alone but increased to 11% 'Yo when cytology and colposcopy were used together, and the overall false negative rate for cytology in patients with all grades of cervical intraepithelial neoplasia was 320/o.' Reassuringly cytology detected all patients with cervical intraepithelial neoplasia grade III (carcinoma in situ). On the other hand, the false negative rate for small grade I and grade II lesions was 58%/0, a finding that was especially alarming since 6% of the population has these lesions. But is it as alarming as it seems? Four fifths of their patients with cervical intraepithelial neoplasia showed evidence of infection with human papillomavirus and since the highest false negative rate was in patients with grade I and grade II cervical intraepithelial neoplasia the debate must be reopened on whether these grades truly reflect a preinvasive disease or whether some are no more than changes caused by infection with human papillomavirus without the potential to progress.
Of a group of 45 patients referred to a colposcopy clinic with cytological abnormality and found to have no more than infection with human papillomavirus, 26 underwent spontaneous regression over a median period of 28 months. 6 Campion et al studied 100 women with cytological and colposcopical evidence of cervical intraepithelial neoplasia grade I and reported that regression over two years occurred in only seven, whereas the lesion progressed to cervical intraepithelial neoplasia grade III Everyone working in cervical cytology aims to detect and treat cervical intraepithelial neoplasia, but until the true importance of cervical intraepithelial neoplasia grades I and II and infection with human papillomavirus is known there will be different opinions on whether to treat these minimal lesions. Until this question is resolved many women, especially young women, will suffer the anxiety of referral to colposcopy clinics and may even be subjected to treatment which will eventually be shown to have been unnecessary. Individual units have done their best to resolve these problems, but surely the time has now come when we should establish a multicentre prospective study finally to settle the problem. 
